Table 1.
Baseline characteristics and surgical/pathological outcomes of included stage III patients (n = 664)
| Variable | Value |
|---|---|
| Sex | |
| Male | 410 (65.71) |
| Female | 214 (34.29) |
| Age (years), mean(s.d.) | 58.8(9.94) |
| <65 | 440 (70.51) |
| ≥65 | 184 (29.49) |
| BMI (kg/m 2 ), mean(s.d.) | 23.12(3.061) |
| Race, Chinese, % | 100.0 |
| Smoking history* | |
| Current/past | 160 (29.04)/112 (20.33) |
| Never | 279 (50.64) |
| Histological subtype | |
| LUAD | 382 (61.22) |
| LUSQ | 128 (20.51) |
| Other | 114 (18.27) |
| cT status | |
| T1 | 225 (33.89) |
| T2 | 250 (37.65) |
| T3–T4 | 189 (28.46) |
| Maximum tumour diameter (cm) | |
| Mean(s.d.) | 4.03(2.20) |
| Median (i.q.r.) | 3.50 (2.50–5.00) |
| cN status (based on preoperative staging) | |
| N0 | 62 (9.34) |
| N1 | 269 (30.51) |
| N2 | 320 (48.19) |
| N3 | 13 (1.96) |
| EGFR status† | |
| Positive | 110 (16.57) |
| Negative | 158 (23.80) |
| PD-L1 expression‡ | |
| <1% | 91 (64.08) |
| 1% to <25% | 29 (20.42) |
| 25% to <50% | 7 (4.93) |
| ≥50% | 15 (10.56) |
Values are n (%) unless otherwise indicated. *Smoking history data were unavailable for 48 patients. †EGFR status examination was not performed for 396 patients. ‡PD-L1 expression examination was not performed for 522 patients. LUAD, lung adenocarcinoma; LUSQ, lung squamous cell carcinoma; EGFR, epidermal growth factor receptor; PD-L1, programmed death ligand 1.